LabCorp v. Ravgen: Federal Circuit Affirms Patent Unpatentable After 731 Days
Laboratory Corporation of America Holdings successfully challenged Ravgen’s US7332277B2 — a patent covering methods for detection of genetic disorders — before the Federal Circuit. The court affirmed the unpatentability finding, delivering a significant blow to Ravgen’s enforcement campaign after a two-year appellate battle.
Federal Circuit Ends Ravgen’s Genetic Disorder Detection Patent Enforcement
Laboratory Corporation of America Holdings (LabCorp) filed this appeal at the Court of Appeals for the Federal Circuit on 6 January 2023, challenging a prior ruling concerning Ravgen’s US7332277B2. The patent in dispute — filed under application number US10/661165 — claims methods for the detection of genetic disorders, a technology central to prenatal and oncology diagnostic testing. LabCorp, one of the largest clinical laboratory networks in the United States, sought appellate confirmation that the patent should be held unpatentable.
On 6 January 2025, the Federal Circuit issued its order affirming the unpatentability determination, closing the case exactly 731 days after filing. An affirmance at this level means the appellate panel found no reversible error in the lower tribunal’s reasoning or legal conclusions. For Ravgen, the ruling extinguishes the enforceability of US7332277B2, removing a key assertion vehicle the company had deployed in its broader licensing and litigation campaign across the diagnostics sector.
The 731-day duration is consistent with contested Federal Circuit appeals involving complex patentability questions, though it sits toward the longer end of the typical range. The affirmance suggests the lower tribunal’s invalidity analysis was well-grounded, leaving Ravgen with limited options — a petition for rehearing en banc or certiorari to the Supreme Court. The public record does not disclose whether any licensing revenue or settlement discussions preceded the final ruling, nor whether co-pending district court actions involving Ravgen’s patent portfolio remain active.
Filing to Unpatentable in 731 days
731 days — above average for a Federal Circuit patent appeal, which typically closes in 18–24 months
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower invalidity ruling is now final
When the Federal Circuit issues an ‘AFFIRMED’ order, it confirms that the tribunal below committed no reversible error in law or fact. The unpatentability finding reached earlier in the proceeding now carries full appellate authority. Ravgen cannot re-litigate these invalidity grounds in a new proceeding. The claims of US7332277B2 are effectively extinguished as an enforcement tool unless Ravgen pursues en banc rehearing or Supreme Court certiorari — both low-probability paths.
No reversible error foundRavgen loses enforceability of a core diagnostics patent
For Ravgen, affirmance of unpatentability is a decisive loss. US7332277B2 — covering methods for detection of genetic disorders — is cancelled and unenforceable. Any ongoing licensing negotiations premised on this patent lose their legal foundation. Ravgen’s ability to assert the ‘277 patent in parallel district court matters or future licensing demands is eliminated. Companies that had previously received demand letters or entered licences under pressure from this patent may reassess their exposure.
Patent cancelled, unenforceableLabCorp secures freedom to operate in genetic disorder testing
The affirmance vindicates LabCorp’s challenge strategy and removes a litigation overhang on its genetic disorder detection methods. LabCorp and similarly-positioned diagnostics laboratories can now operate without licensing risk from US7332277B2. The ruling also strengthens LabCorp’s position in any co-pending matters involving related Ravgen patents, demonstrating the Federal Circuit’s willingness to uphold unpatentability findings in this technology domain. Costs of further appeal now fall to Ravgen.
FTO secured for LabCorpDiagnostics sector gets clearer IP landscape for prenatal testing methods
The Federal Circuit’s affirmance raises the bar for patent assertion entities seeking to enforce broad method patents covering genetic disorder detection and cell-free DNA diagnostics. Laboratories, sequencing companies, and diagnostics platforms operating in the non-invasive prenatal testing (NIPT) and oncology diagnostics space may cite this ruling in opposition to similar claims. The decision suggests that prior-art-based unpatentability arguments carry significant weight at the Federal Circuit in this domain, consistent with the court’s broader scrutiny of diagnostic method patents.
Reduced PAE risk in diagnosticsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Laboratory Corporation of America Holdings | Company | Major US clinical laboratory network — challenger of US7332277B2 on unpatentability groundsSearch in Eureka ↗ |
| Defendant | Ravgen, Inc. | Company | Ravgen, Inc. — patent assertion entity holding diagnostics-related genetic disorder detection patentsSearch in Eureka ↗ |
| Plaintiff counsel | Tina Williams McKeon | Attorney | Counsel for Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Plaintiff law firm | Kilpatrick Townsend & Stockton, LLP | Law Firm | Representing Laboratory Corporation of America HoldingsSearch in Eureka ↗ |
| Defendant counsel | Brian Matty | Attorney | Counsel for Ravgen, Inc.Search in Eureka ↗ |
| Defendant law firm | Desmarais LLP | Law Firm | Representing Ravgen, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a merits affirmance of the unpatentability finding below. The phrasing indicates the panel conducted substantive review and found no reversible legal error. Under the applicable appellate standard, factual findings underpinning unpatentability are reviewed for substantial evidence and legal conclusions de novo. The affirmance forecloses re-litigation of the cancelled claims and strengthens the persuasive authority of the underlying invalidity analysis in related proceedings.
US7332277B2 — Methods for Detection of Genetic Disorders
US7332277B2, filed under application number US10/661165, claims methods for the detection of genetic disorders. The patent sits within the cell-free DNA diagnostics domain — a technology area that underpins non-invasive prenatal testing (NIPT) and has expanding applications in oncology liquid biopsy. The application’s filing period placed it at the early commercial development of cell-free fetal DNA techniques, making priority date and prior art scope significant factors in any patentability challenge. The Federal Circuit’s affirmance confirms that the claims did not survive unpatentability review.
Strategically, US7332277B2 represented a broad assertion vehicle in a commercially lucrative diagnostics category. NIPT and genetic disorder detection are high-revenue segments attracting major laboratory operators, sequencing companies, and digital health platforms. The patent’s cancellation removes a licensing pressure point from Ravgen’s enforcement toolkit, but companies in this space should remain alert to related patents in the Ravgen portfolio that may cover overlapping technical ground. Comprehensive claim mapping against surviving family members is strongly advisable for any entity operating diagnostic workflows that touch cell-free DNA analysis.
Should your team run an FTO analysis against Ravgen’s diagnostics patent family?
Any laboratory, sequencing company, or digital health platform operating in non-invasive prenatal testing, cell-free DNA analysis, or genetic disorder detection workflows should treat this affirmance as a trigger for a portfolio-level FTO review — not a clear signal. US7332277B2 is cancelled, but Ravgen holds additional patents in the genetic disorder detection space. If your products or service lines involve methods that process cell-free nucleic acids for diagnostic purposes, related Ravgen claims may still create exposure. The cancelled ‘277 patent’s claim language is also instructive for identifying potentially overlapping active claims in the family.
PatSnap Eureka’s FTO Search Agent can rapidly map your product’s technical features against the full Ravgen patent family — including continuation applications and related filings — to identify active claims that may require design-around or licensing consideration. Eureka’s AI-powered claim analysis surfaces validity risk signals, prosecution history estoppel, and prior art anchors relevant to cell-free DNA diagnostic method claims, enabling your IP and R&D teams to make informed go/no-go decisions with speed and precision.
Run a freedom-to-operate analysis on US7332277B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Appeals in Genetic Diagnostics Patent Invalidity
Cases involving Federal Circuit review of diagnostic method patent unpatentability — particularly cell-free DNA and genetic disorder detection — most relevant to this appeal.
What this case signals for the diagnostics and genetic testing IP landscape
The Federal Circuit’s affirmance in LabCorp v. Ravgen has ripple effects across cell-free DNA diagnostics, NIPT, and genetic disorder detection IP strategy.
Unpatentability affirmances reshape PAE enforcement in diagnostics
The Federal Circuit’s willingness to affirm unpatentability of a method patent covering genetic disorder detection signals that broad claim portfolios in diagnostic methods face meaningful appellate scrutiny. Patent assertion entities operating in NIPT and cell-free DNA diagnostics should reassess the strength of their claim sets before initiating enforcement campaigns against well-resourced laboratory operators.
LabCorp’s appellate win offers a template for validity challenges in this space
Laboratories and diagnostics companies facing Ravgen-type assertions should study the invalidity arguments that succeeded at the Federal Circuit. The affirmance confirms that the unpatentability analysis survived appellate review, suggesting a replicable challenge pathway for similarly situated defendants. Engaging appellate specialists with Federal Circuit diagnostic-method experience early in proceedings is consistent with LabCorp’s approach here.
Laboratory v Ravgen — key questions answered
The Federal Circuit affirmed the unpatentability of Ravgen’s US7332277B2 in case 23-1345. The order — issued on 6 January 2025 — confirmed the lower tribunal’s finding that the patent covering methods for detection of genetic disorders is unpatentable. The patent is therefore cancelled and unenforceable against LabCorp and other parties.
US7332277B2 claims methods for the detection of genetic disorders, with application to cell-free DNA diagnostic techniques used in non-invasive prenatal testing and related genomic diagnostics. Ravgen asserted this patent against LabCorp as part of a broader enforcement campaign in the diagnostics sector. The patent’s cancellation on unpatentability grounds ends its use as a licensing or litigation vehicle.
An affirmance means the Federal Circuit found no reversible error in the unpatentability finding — the cancelled claims carry no further legal force. For diagnostics companies previously facing demand letters citing US7332277B2, the ruling removes that specific exposure. However, Ravgen’s broader patent portfolio may include related claims, and a full freedom-to-operate analysis against surviving family members remains advisable.
Ravgen’s options after a Federal Circuit affirmance are limited. The company could petition for rehearing en banc — asking the full Federal Circuit to reconsider the panel’s decision — or seek a writ of certiorari from the US Supreme Court. Both routes have low grant rates in patent validity cases. The public record does not indicate whether Ravgen has pursued either avenue following the January 2025 ruling.
The appeal ran for exactly 731 days, filed on 6 January 2023 and closed on 6 January 2025. This is toward the longer end of the typical Federal Circuit appeal timeline, which generally resolves in 18–24 months for patent cases. The duration is consistent with contested patentability appeals requiring substantive analysis of prior art and claim scope.
PatSnap Eureka searches patents and litigation data to answer instantly.